Apply for Xeljanz (Tofacitinib) Copay Assistance Now

Xeljanz copay assistance refers to financial support programs that help patients afford their tofacitinib prescription by reducing or eliminating out-of-pocket costs. These programs include manufacturer copay cards, independent charitable foundations, and patient assistance programs that work alongside your existing insurance coverage to make this specialty medication more accessible.

The manufacturer copay card program typically provides the most substantial savings for commercially insured patients, often reducing copays to a minimal amount per prescription. These programs work by covering the gap between what your insurance pays and your pharmacy cost, up to a maximum annual benefit amount.

At QuickRx Specialty Pharmacy, we coordinate all aspects of Xeljanz copay assistance on your behalf. Our patient navigators evaluate your insurance coverage, identify all programs you qualify for, complete the necessary applications, and manage your enrollment throughout treatment — at no cost to you.

To begin accessing Xeljanz copay assistance, contact QuickRx at (917) 830-2525 or complete the form on this page.

Eligibility for Xeljanz copay assistance varies depending on the specific program type and your insurance coverage. Generally, manufacturer copay card programs are available to patients with commercial or private health insurance who have a valid prescription for Xeljanz or Xeljanz XR. These programs typically exclude patients covered by government-funded insurance such as Medicare, Medicaid, TRICARE, or VA benefits due to federal anti-kickback regulations.

For patients with government insurance, or those who are uninsured or underinsured, alternative assistance options are available through independent charitable foundations and manufacturer patient assistance programs. These programs have their own eligibility criteria, which may include income verification, residency requirements, and documentation of insurance status.

QuickRx Specialty Pharmacy conducts a comprehensive assessment of your specific situation, identifies all programs you may qualify for, and maximizes your potential savings by layering multiple assistance sources when permitted. Even if you’ve been denied assistance elsewhere, our experienced team may find alternative pathways you haven’t explored. Call (917) 830-2525 to get started.

No, QuickRx Specialty Pharmacy provides all copay assistance services completely free of charge to patients. Our commitment to patient care means financial barriers should never prevent someone from accessing the specialty medications they need. You will never receive a bill from QuickRx for copay assistance enrollment, application preparation, program management, or any related support services.

Our patient navigators are dedicated solely to helping you access affordable medication. This no-cost service extends throughout your entire treatment journey, including initial enrollment, annual renewals, appeals of denied applications, and transitions between programs as your situation changes.

Xeljanz (tofacitinib) is an oral Janus kinase (JAK) inhibitor in the pharmacologic category of disease-modifying antirheumatic drugs (DMARDs). It was FDA-approved on November 6, 2012, and works by inhibiting JAK enzymes — intracellular enzymes involved in stimulating immune cell function. By blocking these pathways, tofacitinib reduces inflammation and modulates the immune response driving several chronic conditions.

Xeljanz has the following FDA-approved labeled indications in adults: rheumatoid arthritis (moderately to severely active, in patients with inadequate response or intolerance to one or more TNF blockers); psoriatic arthritis (active); ulcerative colitis (moderately to severely active, induction and maintenance of remission); and ankylosing spondylitis (active). In pediatric patients aged 2 years and older, Xeljanz is approved for polyarticular course juvenile idiopathic arthritis (pJIA) and psoriatic arthritis.

Xeljanz is available as immediate-release (IR) tablets (5 mg, 10 mg), an oral solution (1 mg/mL), and as Xeljanz XR extended-release tablets (11 mg, 22 mg). No generic equivalent is currently available in the United States. Call us at (917) 830-2525 to explore financial assistance options.

Xeljanz (tofacitinib) may be taken with or without food. The extended-release tablet (Xeljanz XR) must be swallowed whole and intact — it should not be crushed, split, or chewed. The inert tablet shell of the XR formulation may occasionally be visible in the stool; this is normal and does not indicate the medication was not absorbed.

Adult dosing varies by condition and formulation and is determined by your prescribing physician. When transitioning from the IR tablet to the XR tablet, the XR tablet begins the day following the last IR dose — the two forms are not interchangeable on a mg-to-mg basis.

For pediatric patients with polyarticular course juvenile idiopathic arthritis (children ≥2 years weighing ≥10 kg), dosing is weight-based using the oral solution (1 mg/mL): 3.2 mg twice daily for 10–<20 kg; 4 mg twice daily for 20–<40 kg; and 5 mg twice daily for ≥40 kg. Pediatric patients ≥40 kg may also use the immediate-release tablet at 5 mg twice daily.

Before starting Xeljanz, therapy should not be initiated in patients with an absolute lymphocyte count below 500 cells/mm³, ANC below 1,000 cells/mm³, or hemoglobin below 9 g/dL. All age-appropriate immunizations should be completed before starting therapy, and live vaccines should not be given during treatment.

Xeljanz requires dose adjustments in patients with kidney impairment or moderate liver impairment, as tofacitinib exposure increases significantly in these populations.

Kidney impairment (CrCl ≤50 mL/minute): IR 5 mg twice daily reduces to 5 mg once daily; IR 10 mg twice daily reduces to 5 mg twice daily; XR 11 mg once daily transitions to IR 5 mg once daily; XR 22 mg once daily reduces to 11 mg once daily. No adjustment is needed for CrCl above 50 mL/minute. On hemodialysis days, administer after the dialysis session.

Liver impairment: Mild (Child-Pugh Class A) — no adjustment needed. Moderate (Child-Pugh Class B) — dose reduction required across all formulations. Severe (Child-Pugh Class C) — use is not recommended and has not been studied, including in patients with hepatitis B or C.

Your prescribing physician and pharmacist will evaluate your kidney and liver function and adjust your prescription accordingly. Call (917) 830-2525 with any questions about your dosing.

The most common side effects occurring in more than 10% of patients include infection (20–22%), nasopharyngitis (3–14%), and elevated lipids including increased LDL cholesterol (15–19%) and increased HDL cholesterol (10–12%).

Side effects occurring in 1% to 10% of patients include skin rash (6%), headache (3–9%), diarrhea (3–5%), nausea (4%), upper respiratory tract infection (4–7%), herpes zoster infection (1–5%), increased creatine phosphokinase (3–7%), anemia (2–4%), urinary tract infection (2%), and hypertension (2%).

Less common side effects reported without a defined frequency include peripheral edema, abdominal pain, fatigue, insomnia, musculoskeletal pain, arthralgia, cough, dyspnea, and interstitial lung disease. Your healthcare team will monitor you regularly for side effects during treatment. Always report any new or worsening symptoms to your prescriber promptly.

Xeljanz carries a US Boxed Warning — the FDA’s most serious warning — covering five major safety concerns:

Serious Infections: Tofacitinib can increase the risk of serious bacterial, viral, and fungal infections including tuberculosis, cryptococcosis, histoplasmosis, and cytomegalovirus. Screen for TB and viral hepatitis before starting treatment. Interrupt therapy if a serious infection develops.

Mortality: In a clinical trial in RA patients ≥50 years old with at least one cardiovascular risk factor, a higher rate of all-cause mortality — including sudden cardiovascular death — was observed with tofacitinib versus TNF blockers.

Malignancies: Lymphomas and other malignancies including malignant melanoma, non-melanoma skin cancers, and lung carcinoma have been reported. Periodic skin examinations are recommended for patients at increased risk.

Major Adverse Cardiovascular Events (MACE): Higher rates of non-fatal myocardial infarction, non-fatal stroke, and cardiovascular death have been observed versus TNF blockers, particularly in current or past smokers with cardiovascular risk factors.

Thrombosis: Deep vein thrombosis, pulmonary embolism, and arterial thrombosis have been observed. Avoid use in patients at increased thrombosis risk and discontinue immediately if symptoms develop.

Contact your healthcare provider immediately for chest pain, shortness of breath, signs of infection, unusual skin changes, severe abdominal pain, or leg swelling or pain.

Hypersensitivity: Reactions including angioedema and urticaria have been reported. Discontinue therapy for any serious reactions.

Interstitial Lung Disease (ILD): ILD has been reported, particularly in patients also receiving methotrexate. Use with caution in patients with a history or risk of ILD or pre-existing chronic lung disease.

GI Perforation: Has been reported, particularly in patients also taking NSAIDs or corticosteroids. Report severe or worsening abdominal pain immediately.

Immunosuppressant Combinations: Do not combine Xeljanz with biologic DMARDs, strong immunosuppressants (azathioprine, tacrolimus, cyclosporine), or potent immunosuppressive chemotherapy.

Surgery: Hold tofacitinib for at least 3 days prior to elective hip or knee replacement surgery. Restart once the wound shows evidence of healing (typically ~14 days post-surgery).

Xeljanz XR and GI Narrowing: Use caution in patients with severe GI narrowing — rare obstructive symptoms have occurred with non-deformable ER formulations in patients with known strictures.

Older Adults: Patients ≥65 years had a higher frequency of serious infections in clinical trials. Appropriate caution, education, and monitoring should be implemented.

Yes. Tofacitinib is metabolized primarily by CYP3A4 (major pathway) and CYP2C19 (minor pathway), meaning drugs that affect these enzymes can alter tofacitinib blood levels.

Strong CYP3A4 Inhibitors (e.g., certain antifungals, HIV medications, fluconazole): Increase tofacitinib exposure — dose reductions are required. Grapefruit juice may also increase levels.

Strong CYP3A4 Inducers (e.g., rifampin, certain anticonvulsants): May decrease tofacitinib levels, potentially reducing effectiveness. Avoid concurrent use where possible.

Biologic DMARDs and Immunosuppressants: Combining Xeljanz with biologic DMARDs (TNF inhibitors, IL-6 inhibitors) or potent immunosuppressants (azathioprine, cyclosporine, tacrolimus) is contraindicated due to additive immunosuppression risk.

Vaccines: Live vaccines should be avoided during therapy. Non-live vaccines should ideally be administered at least 2 weeks before starting tofacitinib. Rheumatology guidelines recommend holding tofacitinib 1–2 weeks after vaccine administration when disease activity permits.

Always inform all healthcare providers of every medication, supplement, and herbal product you take. Our QuickRx pharmacists review drug interactions as part of our clinical services — call (917) 830-2525 with any questions.

Per prescribing guidelines, required monitoring includes: lymphocyte count at baseline and every 3 months; neutrophil and platelet counts at baseline, after 4–8 weeks, and every 3 months; hemoglobin at baseline, after 4–8 weeks, and every 3 months; lipids (LDL, HDL, total cholesterol, triglycerides) at 4–8 weeks after initiation and periodically; liver function tests at baseline and periodically; viral hepatitis screening before starting therapy; and tuberculosis screening at baseline.

During treatment, your provider will also monitor for signs of infection (including TB reactivation), abdominal symptoms that could suggest GI perforation, and cardiovascular symptoms. Heart rate and blood pressure should be checked at baseline and periodically. Periodic skin examinations are recommended for patients at increased skin cancer risk.

Dose adjustments or interruptions are required if laboratory values fall outside thresholds — therapy must be interrupted for lymphocytes below 500 cells/mm³, ANC persistently 500–1,000 cells/mm³, or hemoglobin below 8 g/dL. Therapy must be discontinued for confirmed lymphocytes below 500 cells/mm³ or ANC below 500 cells/mm³.

Kidney impairment: CrCl above 50 mL/minute — no dose adjustment needed. CrCl ≤50 mL/minute — dose reduction required, as tofacitinib AUC increases approximately 1.75–2.5-fold in moderate to severe renal impairment.

Liver disease: Mild impairment (Child-Pugh Class A) — no adjustment. Moderate (Child-Pugh Class B) — dose reduction required. Severe (Child-Pugh Class C) — not recommended; not studied in patients with hepatitis B or C.

Cardiovascular disease: Patients with existing cardiovascular disease or risk factors — including smokers and former smokers ≥50 years old — carry increased MACE risk. Cardiovascular risk factors should be optimized before and throughout treatment.

Lung disease: Patients with chronic lung disease or a history of ILD may be more prone to infections. Discuss any lung conditions with your prescriber before starting Xeljanz.

Active infections or TB: Xeljanz must not be started in patients with active infections, including localized ones. Latent TB must be treated prior to initiating tofacitinib. Always share your complete medical history with your prescribing physician and QuickRx pharmacist. Call (917) 830-2525 with any questions.

Ulcerative colitis (UC) is a chronic inflammatory bowel disease that causes inflammation and ulcers in the lining of the large intestine and rectum. Symptoms include persistent diarrhea (often with blood or pus), abdominal pain and cramping, rectal bleeding, urgency to defecate, weight loss, and fatigue. UC is a lifelong condition that typically follows a relapsing-remitting course.

Xeljanz is FDA-approved for the treatment of moderately to severely active ulcerative colitis in adults who have had an inadequate response or intolerance to one or more TNF blockers — for both induction and maintenance of remission. Tofacitinib works by inhibiting JAK enzymes that drive the inflammatory cytokine signaling responsible for colonic inflammation, helping decrease inflammation, promote mucosal healing, and support remission.

The American Gastroenterological Association also suggests JAK inhibitors like tofacitinib can be used as an early advanced therapy option in moderate to severely active UC, not solely after TNF blocker failure. Monitoring for UC patients on Xeljanz includes colonoscopy, fecal calprotectin, and serial C-reactive protein to assess disease activity and treatment response.

Rheumatoid arthritis (RA) is a chronic autoimmune disease in which the immune system mistakenly attacks the synovium — the lining of the membranes surrounding the joints. This causes persistent joint inflammation, pain, swelling, stiffness, and over time can lead to joint damage and loss of function. RA typically affects multiple joints symmetrically and can also involve the lungs, heart, and eyes.

Xeljanz is FDA-approved for moderately to severely active RA in adults with inadequate response or intolerance to one or more TNF blockers. Tofacitinib inhibits the JAK-STAT signaling pathway, reducing circulating inflammatory markers like C-reactive protein, decreasing CD16/56+ natural killer cell activity, and modulating immunoglobulin levels.

Xeljanz can be used as monotherapy or in combination with non-biologic DMARDs such as methotrexate at antirheumatic doses. It should not be combined with biologic DMARDs or potent immunosuppressants. Your rheumatologist will determine the most appropriate approach for your situation.

Both Xeljanz tablets and oral solution should be stored at room temperature: 20°C to 25°C (68°F to 77°F). Excursions are permitted between 15°C and 30°C (59°F and 86°F). Do not repackage tablets into pill organizers or other containers.

For the oral solution: store in the original container and protect from light. Discard any unused oral solution 60 days after first opening the bottle. After each use, store the bottle in the original carton, rinse the oral syringe with water, and allow it to air dry.

Tofacitinib is classified as a hazardous drug (NIOSH 2024). Follow appropriate precautions for handling, storage, and disposal per NIOSH and USP 800 recommendations. Keep all formulations out of reach of children and pets. Contact your QuickRx pharmacist at (917) 830-2525 with any questions about storage.

QuickRx Specialty Pharmacy is a nationwide specialty pharmacy licensed in all 50 states with deep expertise in autoimmune and inflammatory disease medications like Xeljanz. Our dedicated pharmacists and patient navigators understand the unique challenges of managing rheumatoid arthritis, ulcerative colitis, psoriatic arthritis, and ankylosing spondylitis — and provide comprehensive support to ensure you can access and afford your medication throughout treatment.

Our copay assistance expertise sets us apart. We maintain current knowledge of all available Xeljanz assistance programs and handle the time-consuming work of identifying programs, preparing applications, and managing enrollments — at no cost to you. Note that Xeljanz is only available through specialty/network pharmacies, and our team specializes in navigating these access requirements seamlessly.

Beyond copay assistance, QuickRx provides clinical pharmacy services including drug interaction review, administration counseling, side effect management, prior authorization support, convenient home delivery, and refill reminders. We accept most insurance plans. Contact us today at (917) 830-2525 to get started.